Our Brands｜General Biologicals Corporation

All-in-One Molecular System - GBC AIO M160

English 繁體中文

Offering a new era for consumers, GBC’s medical technologies combine ease of use with effective results

GBC has new innovated products that are created to be used at clinics and laboratories for preventives and cancer diagnosis. You may find new technologies and information on clinics and laboratories that provide medical services.

oh care

a range of product lines that keep you healthy by orally balancing the good and bad bacteria.

Danner Laboratory & CurieMed Laboratory

GBC is partnering with professional laboratories and clinics to provide groundbreaking diagnostic solutions.

Offering fast, accurate diagnostic results that allow for the early detection and treatment of any number of health issues, our diagnostic solutions are available in clinics and laboratories worldwide.

Danner Laboratory (USA)

Utilizing the most innovative cytology, pathology,
and molecular testing technology while serving as
a strategic partner for hospitals, clinics and laboratories.

Danner Laboratory (Canada)

providing accurate, expedient, diagnostic results allowing for early detection, treatment and improved health outcomes.

CurieMed Laboratory (Taiwan)

providing specialized medical laboratory tests and services through a network of primary clinical laboratories and clinics.

COVID-19 Testing

Offering a range of highly accurate yet remarkably affordable COVID-19 tests, GBC is helping to put the pandemic behind us.

Exploring New Trends in the Field of Medical Technology - Precision Medicine

Recently, the Genetic Nutrition Functional Medicine Association, in collaboration with GBC and Leopard Gene, jointly organized a seminar on "Precision Medicine in Comprehensive Health" that garnered significant attention from the medical and industry sectors.

GBC Starts Carbon Inventory Project to Grasp Carbon Management and Net-Zero Trends

Due to the crisis of global warming and climate change, the Taiwanese government responded to international initiatives in 2022 by actively declaring a commitment to achieve net-zero emissions by 2050. In February 2023, they passed the Climate Change Response Act and established a carbon trading market in August of the same year. In 2024, carbon fees were imposed on domestic carbon-intensive industries and major carbon emitters to incentivize companies to reduce emissions. Particularly significant was the commencement in October 2023 of the European Union's Carbon Border Adjustment Mechanism (CBAM) transitional phase, which required the declaration of product carbon emissions-related information. Starting in 2026, CBAM certificates will be levied, impacting an estimated over one hundred thousand export supply chain companies across Taiwan.

GBC CellBio™ Technology Platform received the Bronze Award at the National Pharmaceutical Technology & Research Development Awards.

GBC was nominated for the 112th National Pharmaceutical Technology & Research Development Awards jointly hosted by Taiwan's Food and Drug Administration of the Ministry of Health and Welfare and the Industrial Development Bureau of the Ministry of Economic Affairs for its CellBio™technology platform product.

Latest COVID-19 Variants: A Detailed Overview

Throughout the years, we've learned a fundamental truth about viruses: they're always evolving. With the persistent threat of COVID-19, it's become clear that as the virus encounters new populations and environments, it morphs into various strains.

GB COVID-19 Ag Rapid Test: Latest Update

As the COVID-19 virus continues to morph into various forms — including the XBB.1.5 variant or the "Kraken" as some are calling it — staying on top of testing strategies is more essential than ever. At General Biologicals Corporation (GBC), we understand the importance of continuous research and timely updates for our COVID-19 Ag Rapid Test. So, let's delve into the latest updates.

Revolutionizing Oral Care With P113 Peptide Technology

Learn how GBC has turned an antibacterial protein into a safe and effective oral healthcare product for families.

The Future of Molecular Diagnostics

A Brief Look at the Advancements in Real-Time PCR Technology

Introduction to Clinical Detection Techniques for Pathogens

Learn how GBC develops fast and accurate ELISA and RT-PCR products in short period of time

Artificial Intelligence in the Clinical Diagnosis of Cancer Cells

GBC is cooperating with Danner Lab of the US to establish AI for cervical cancer cell diagnosis. A panoramic smear is cut into digital cell images, and a liquid-based thin smear can be cut into about 2,300 slices .

Discussion of Ct Value Calculation and Clinical Implications

COVID-19 appeared at the end of 2019 and swept across the world. By the end of May of this year, the total number of confirmed cases in Taiwan had reached 2,032,983 and the number of confirmed cases in a single day had climbed to more than 80,000. Meanwhile, terms like “PCR” and “Ct value” have made a frequent appearance in our lives.

Analysis of Differences between Lateral Flow Rapid Screening and PCR for SARS-CoV-2

COVID-19 began sweeping across the world starting from late 2019 and the pandemic continues to this day.

More in diagnostic testing

Vision

To be the global benchmark for the manufacture and provision of diagnostics and healthcare technologies.

Mission

To create and implement the use of state-of-the-art diagnostic technologies that enhance the lives of people worldwide.